Related references
Note: Only part of the references are listed.Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials
Kuaifa Fang et al.
HEART FAILURE REVIEWS (2021)
Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Nevin Hammam et al.
CURRENT RHEUMATOLOGY REVIEWS (2021)
The forgotten right ventricle in cardio-oncology
Eiman Jahangir et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2020)
A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients
Angeline Ginzac et al.
BMC CANCER (2020)
Protective strategies to prevent trastuzumab-induced cardiotoxicity
Shaohua Guo et al.
LANCET (2020)
The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients
Sherry-Ann Brown et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Chondroid and Osseous Metaplasia of the Central Fibrous Body in Adolescent Hearts With Mutations inTNNI3andTNNT2genes
Chrystalle Katte Carreon et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2020)
The Role of Biomarkers in Cardio-Oncology
Kajaluxy Ananthan et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2020)
African Vegetables (Clerodendrum volibile Leaf and Irvingia gabonensis Seed Extracts) Effectively Mitigate Trastuzumab-Induced Cardiotoxicity in Wistar Rats
Olufunke Olorundare et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
Raphaelle Corremans et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2019)
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
Filippo Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2019)
The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity
Julia B. Blanter et al.
CARDIOLOGY IN REVIEW (2019)
Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials
Yingxu Ma et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
EFFECTS OF THE COMBINATIONS OF AMLODIPINE WITH AN LISINOPRIL OR A CARVEDILOL IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY
M. Bubnova et al.
JOURNAL OF HYPERTENSION (2019)
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer
Maya Guglin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Areas of Cartilaginous and Osseous Metaplasia After Experimental Myocardial Infarction in Rats
Catalin Gabriel Manole et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2019)
Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report
Takahiko Gibo et al.
MOLECULAR AND CLINICAL ONCOLOGY (2019)
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy
Muthiah Vaduganathan et al.
JACC: CARDIOONCOLOGY (2019)
A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab
P. Munster et al.
CANCER RESEARCH (2019)
Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy +/- trastuzumab
Dorothy M. Gujral et al.
BREAST (2018)
Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events
Matthias Pinter et al.
CLINICAL CANCER RESEARCH (2018)
PREVENTION OF CHEMO-INDUCED CARDIOTOXICITY WITH BETA-BLOCKERS
Purva Sharma et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
Stefania Gorini et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production
Gennaro Riccio et al.
FRONTIERS IN PHYSIOLOGY (2018)
Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
Ozlem Yersal et al.
CARDIOLOGY RESEARCH AND PRACTICE (2018)
Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer
Saranrat Wittayanukorn et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Simple spectrophotometric assay for measuring catalase activity in biological tissues
Mahmoud Hussein Hadwan
BMC BIOCHEMISTRY (2018)
The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis
Ming Yuan et al.
CARDIOVASCULAR THERAPEUTICS (2018)
Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia
Myat Su Bo et al.
JOURNAL OF NUTRITION AND METABOLISM (2018)
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond
Daniela Di Lisi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity
Edith Pituskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy
Hanna-Riikka Teppo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
Ibrahim Sadek et al.
GENES & DISEASES (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population
M. Rushton et al.
CURRENT ONCOLOGY (2017)
Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study
Ashita Barthur et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2017)
Molecular mechanisms of trastuzumab-mediated cardiomyopathy: Implications of autophagy in trastuzumab-induced cardiotoxicity
Nishant Mohan et al.
CANCER RESEARCH (2016)
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
Geeta Gulati et al.
EUROPEAN HEART JOURNAL (2016)
Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials
Katarzyna Rygiel
INDIAN JOURNAL OF PHARMACOLOGY (2016)
Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women
Jobert Richie N. Nansseu et al.
LIPIDS IN HEALTH AND DISEASE (2016)
Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial
Annelies H. Boekhout et al.
JAMA ONCOLOGY (2016)
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
Anthony F. Yu et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
Gauri Akolkar et al.
CARDIOVASCULAR ULTRASOUND (2015)
Myocardial Protection During Cardiotoxic Chemotherapy
Ronald M. Witteles et al.
CIRCULATION (2015)
Renal effects of targeted anticancer therapies
Camillo Porta et al.
NATURE REVIEWS NEPHROLOGY (2015)
Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin
Gang Hao et al.
XENOBIOTICA (2015)
Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial
Joannes A. A. Reijers et al.
EBIOMEDICINE (2015)
Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy
Anna Calleja et al.
JOURNAL OF ONCOLOGY (2015)
A Rare Case of Paclitaxel and/or Trastuzumab Induced Acute Hepatic Necrosis
Hiren Mandaliya et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2015)
Acute Cardiotoxic Effects of Adjuvant Trastuzumab Treatment and Its Relation to Oxidative Stress
Ahmet Dirican et al.
ANGIOLOGY (2014)
New-Onset Heart Failure in Association With Severe Hypertension During Trastuzumab Therapy
Joerg Herrmann et al.
MAYO CLINIC PROCEEDINGS (2014)
IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
Frency Varghese et al.
PLOS ONE (2014)
Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Ghideon Ezaz et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Virginia Shalkey Hahn et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
Adedayo A. Onitilo et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Nephrotoxicity of recent anti-cancer agents
Norbert Lameire
CLINICAL KIDNEY JOURNAL (2014)
Angiotensin II and Oxidative Stress in the Failing Heart
Daniela Zablocki et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Diabetes mellitus accelerates cartilaginous metaplasia and calcification in atherosclerotic vessels of LDLr mutant mice
Ngoc Nguyen et al.
CARDIOVASCULAR PATHOLOGY (2013)
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
Kirsten Achilles Poon et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
Sylvana Hidalgo et al.
CASE REPORTS IN CARDIOLOGY (2013)
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge
Carlo G. Tocchetti et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
Erin J. Aiello Bowles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Drug-Induced Oxidative Stress and Toxicity
Damian G. Deavall et al.
JOURNAL OF TOXICOLOGY (2012)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
A. L. Jones et al.
BRITISH JOURNAL OF CANCER (2009)
Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways
Leo I. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria:: the VALERIA trial
Jan Menne et al.
JOURNAL OF HYPERTENSION (2008)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
Daniela Cardinale et al.
CIRCULATION (2006)
Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk
Katrien Lemmens et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method
Irfan Rahman et al.
NATURE PROTOCOLS (2006)
Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values
AS Villecco et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2004)
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiornyocytes - Implications for herceptin-induced cardiomyopathy
LP Grazette et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Endochondral bone formation in the heart: A possible mechanism of coronary calcification
LA Fitzpatrick et al.
ENDOCRINOLOGY (2003)
Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection
F Locatelli et al.
KIDNEY INTERNATIONAL (2002)
The plasma parameter log (TG/HDL-C) as an atherogenic index:: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL).
M Dobiásová et al.
CLINICAL BIOCHEMISTRY (2001)
A simple biochemical assay for glutathione S-transferase activity and its possible field application for screening glutathione S-transferase-based insecticide resistance
JG Vontas et al.
PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY (2000)
Share Paper
